AN ACT Relating to restoring funding for cancer research and public health services;
SB 6116 is a Washington state bill titled “Restoring funding for cancer research and public health services.” The bill text provided is heavily garbled, but it appears to amend the state’s tobacco tax and tobacco product definitions in RCW chapter 82. It adds or revises definitions for tobacco-related terms such as tobacco products, cigarette, cigar, distributor, retailer, and taxable sales price, and it includes provisions addressing affiliated and unaffiliated distributors and retailers, as well as products containing tobacco or nicotine, including synthetic nicotine and vapor products in the definitional framework.
The bill also includes emergency and retroactivity language. It states that certain RCW sections do not apply to the act, that the act applies retroactively to January 1 as well as prospectively, and that it is necessary for the immediate preservation of public peace, health, or safety, taking effect immediately. Based on the caption and the structure of the text, the measure appears intended to restore or redirect revenue associated with tobacco taxation to support cancer research and public health services.
If enacted, SB 6116 would modify Washington’s tobacco tax statutes and related definitions in RCW chapter 82, affecting how tobacco products are classified, valued, and taxed. The bill would likely influence the tax obligations of manufacturers, distributors, retailers, and other businesses involved in tobacco and nicotine product sales, including transactions involving affiliated entities and sales into Indian country where applicable. Its emergency clause and retroactive application would make the changes effective immediately and potentially reach back to January 1, affecting prior and current tax treatment.
There is no committee transcript or recorded vote history provided, so there is no direct evidence of debate, amendments, or partisan division in the materials supplied. The bill caption and emergency language suggest a policy goal framed around public health funding, which typically signals support from sponsors seeking to restore revenue for cancer research and health services. However, without recorded discussion or votes, the overall sentiment can only be characterized as unclear from the available record, with the text itself indicating urgency and a public-health rationale.
The main likely points of contention are the bill’s tax implications and its retroactive application. Businesses in the tobacco supply chain—especially manufacturers, distributors, and retailers—could object to changes in taxable sales price definitions, expanded product coverage, or compliance burdens. Another possible area of dispute is the treatment of products containing nicotine, including synthetic nicotine and vapor products, and how the bill interacts with existing tax exemptions or tribal and federal immunity issues. The emergency clause and retroactivity may also be controversial because they can impose immediate and backward-looking obligations.